KSL-W is a member of a decapeptide family with demonstrated effectiveness to prevent biofilm formation on teeth, inhibit the growth of oral microorganisms, and reduce the development of plaque or dental caries. KSL-W mimics the body’s own defense system – namely it exhibits selective toxicity for prokaryotes. The result is efficacy against supragingival plaque bacteria, but little effect on normal oral flora and low potential for drug-resistance. KSL–W is readily adsorbed to toothlike materials and effectively desorbed over time; this peptide also has good stability in saliva.
The U.S. Army Dental and Trauma Research Detachment has formulated this peptide into an antiplaque chewing gum (APCG) for sustained and improved delivery in the mouth. In addition to KSL–W, APCG contains a xylitol base, calcium phosphate as a mild abrasive, and cetylpyridinium chloride which causes a large increase in the rate and extent of KSL–W release. This peptide readily degrades in gastric environments. APCG has extensive pre-clinical testing data and is funded to enter FDA Phase I trials.
- Augments natural defense: KSL-W acts in a manner similar to the body’s defenses and augments those systems in a manner that targets threats while maintaining beneficial oral flora
- Effective: Efficacious against plaque-causing bacteria including: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and cariogenic bacteria (Streptococcus mutans, S. sobrinus, and Lactobacillus acidophilus)
- Broad spectrum capabilities: KSL-W has also been shown to kill fungi including Candida albicans and preliminary data indicates activity against the Herpes simplex virus (type 1) as well as anti-inflammatory capabilities
- Numerous peer-reviewed articles
- US Patent 8,778,889